Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze PTGX stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate PTGX investment potential.

What is PTGX stock price today?

Get real-time PTGX stock price, historical data, and price charts on Financhill. Track PTGX performance with our advanced analysis tools.

Is PTGX a good investment?

Evaluate PTGX investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy PTGX stock?

To buy PTGX stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of PTGX?

View detailed market capitalization data and company valuation metrics for PTGX on our comprehensive analysis page.

What is the P/E ratio of PTGX?

Use our fundamental analysis tools to view PTGX P/E ratio and compare valuation metrics with industry peers.

What are PTGX earnings?

View PTGX earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Protagonist Therapeutics, Inc. Stock Predictions

99.6% Win Rate Across 508 Picks (Third-Party Audited)

See how Decentralized Masters' system identifies 10x-100x opportunities before Coinbase. Watch free training.

Sell

PTGX
Protagonist Therapeutics, Inc.

Last Price:

$83.01

Seasonality Move:

-2.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Coinbase Lost $400M. Your Crypto Isn't Safe on Exchanges.

Stop trusting exchanges. Learn how to access Native Markets where YOU control your assets

Protagonist Therapeutics, Inc. Stock Forecast

Over the next 52 weeks, Protagonist Therapeutics, Inc. has on average historically risen by 48.9% based on the past 9 years of stock performance.
Protagonist Therapeutics, Inc. has risen higher in 6 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%
Is Protagonist Therapeutics, Inc. Stock Undervalued?

The current Protagonist Therapeutics, Inc. [PTGX] share price is $84.79. The Score for PTGX is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
PTGX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Protagonist Therapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Protagonist Therapeutics, Inc. has on average historically risen by 48.9% based on the past 9 years of stock performance.

Protagonist Therapeutics, Inc. Stock Rating

Sell

Protagonist Therapeutics, Inc. (PTGX) is a Sell

Is Protagonist Therapeutics, Inc. overpriced?

Protagonist Therapeutics, Inc. has risen higher in 6 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 66.67%

Protagonist Therapeutics, Inc. Stock Price History

Is PTGX stock going to rise?

Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and PTGX is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

protagonist-inc.com

52-Week Data

52-Week High:

96.54

52-Week Low:

33.70

Prediction Charts

Market Cap:

5.3B

Price in USD:

84.79

Volume:

609.1K

Beta:

1.94

Technical Analysis

SMA50:

86.40

SMA100:

77.47

SMA200:

64.14

52-Wk Change:

129.91%

Stock Predictions

Is Protagonist Therapeutics, Inc. stock public?

Yes, Protagonist Therapeutics, Inc. is a publicly traded company.
What is the Protagonist Therapeutics, Inc. stock quote today?

The Protagonist Therapeutics, Inc. stock price is 84.79 USD today.
How to buy Protagonist Therapeutics, Inc. stock online?

You can buy Protagonist Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Jan-2	86.54	87.18	88.16	85.19
Jan-5	87.53	84.18	87.53	82.92
Jan-6	83.25	82.27	85.00	81.67
Jan-7	82.25	82.34	82.69	79.18
Jan-8	81.05	80.20	82.14	79.22
Jan-9	80.20	80.22	81.40	79.38
Jan-12	79.49	80.25	81.09	78.75
Jan-13	79.88	81.36	82.74	79.64
Jan-14	80.85	85.23	85.30	80.47
Jan-15	84.60	84.75	87.44	84.33
Jan-16	84.51	81.99	84.67	81.47
Jan-20	81.16	83.42	83.63	79.87
Jan-21	82.51	83.89	83.96	80.27
Jan-22	82.83	84.79	85.20	80.65

Protagonist Therapeutics, Inc. Earnings

Protagonist Therapeutics, Inc. Earnings Report: Per Share Protagonist Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Protagonist Therapeutics, Inc. Forecast Revenue Growth

Protagonist Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Protagonist Therapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $1.12 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.93 per share, and a decrease next year of $1.96 per share.

* Protagonist Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.